Purpose The cannabinoid type 2 receptor (CB 2 R) is expressed by immune cells such as monocytes and macrophages. In the brain, CB 2 R is primarily found on microglia. CB 2 R upregulation has been reported in animal models of Alzheimer's disease, with a preferential localization near amyloid beta (Aβ) plaques, and in patients post mortem. We performed in vivo brain imaging and kinetic modelling of the CB 2 R tracer [ ) and distribution volume (V T ) parameters could be used. Brain uptake was generally low with an average K 1 value of 0.07 ml/min/ml tissue. V T and BP ND were in the range of 0.7 -1.8 and 0.6 -1.6, respectively. Test values in HC were about 30 % for V T and BP ND . AD patients showed overall significantly lower CB 2 R binding. No relationship was found between regional or global amyloid load and CB 2 R availability. Conclusion Kinetic modelling of [ 11 C]NE40 is possible with a two-tissue reversible model. In contrast to preclinical and post-mortem data, [
C]NE40 PET scans were performed in eight HC and nine AD patients with full kinetic modelling using arterial sampling and metabolite correction and partial volume correction. All AD patients received a static [ 
and distribution volume (V T ) parameters could be used. Brain uptake was generally low with an average K 1 value of 0.07 ml/min/ml tissue. V T and BP ND were in the range of 0.7 -1.8 and 0.6 -1.6, respectively. Test values in HC were about 30 % for V T and BP ND . AD patients showed overall significantly lower CB 2 R binding. No relationship was found between regional or global amyloid load and CB 2 R availability. Conclusion Kinetic modelling of [ 11 C]NE40 is possible with a two-tissue reversible model. In contrast to preclinical and post-mortem data, [
11 C]NE40 PET shows lower CB 2 R availability in vivo in AD patients, with no relationship to Aβ plaques. A possible explanation for these findings is that [ 
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Aggregated proteins are potent activators of an immune response in the brain that leads to neuroinflammation [2] . In this process, microglia become activated and upregulate an array of receptors that may be critical in microglial regeneration and/or degeneration of the central nervous system (CNS) [3] . Among these are the mitochondrial membrane 18-kDa translocator protein (TSPO), the type 2 cannabinoid receptor (CB 2 R), the P 2 X7 receptor and matrix metalloproteinases [4] . The target of TSPO has been extensively studied using PET imaging approaches over the past decades. [ 11 C]PK11195 shows cortical upregulation of TSPO in different brain regions in AD [5, 6] [4] provide an overview of these radiotracers). CB 2 R is an alternative membrane marker of activated microglial cells and forms part of the endogenous cannabinoid system, together with type 1 cannabinoid receptor (CB 1 R), their endogenous ligands (endocannabinoids), and their transport and degrading enzymes.
Upon microglial activation, CB 2 R expression is also markedly elevated [7] . Studies in small-animal models and postmortem studies in patients have shown upregulation of CB 2 R in various CNS disorders in which neuroinflammation also occurs. A recent study has shown CB 2 R activation in a bigenic mouse model of AD with amyloid beta (Aβ) amyloidosis without concomitant tau pathology [8] . Immunofluorescent analysis showed that CB 2 R expression in activated microglia is the main source for the differential PET signal, while neuronal CB 2 R density is unchanged [8] . Also, in post-mortem brain tissue of AD patients, CB 2 R is selectively upregulated in neuritic plaque-associated glia [9] . In a Huntington's disease transgenic mouse model [10] , microglial CB 2 R was found to play a neuroprotective role, and in animal models of Parkinson's disease, pharmacological agonism of CB 2 R was also found to be protective against nigrostriatal cell loss [11] .
Therefore, CB 2 R PET imaging may provide a novel type of biomarker for neurodegeneration-associated neuroinflammation and could be a valuable tool to guide specific CB 2 R-related therapeutic interventions. A number of PET radiotracers for CB 2 R have been published recently [12] [13] [14] , but so far no human brain CB 2 R PET studies have been published. Our group has developed the CB 2 R tracer 2-oxo-7-[ 11 C]-methoxy-8-butyloxy-1,2-dihydroquinoline-3-carboxylic acid ([ 11 C]NE40), which has favourable affinity (K i = 9.6 nM for CB 2 R) and kinetics for CNS imaging [15] . It has been validated preclinically in animal models with local overexpression of human CB 2 R [16] . The aims of the current study were to evaluate full brain kinetic modelling of [ 11 C]NE40 and to investigate the hypothesis that higher CB 2 R availability is present in vivo in AD brain, colocalized at sites of Aβ deposition.
Materials and methods

Subjects
Healthy controls (HC; men and women, aged >40 years) were recruited through advertisements in a local newspaper and on the departmental website. The main exclusion criteria for HC included a history of major internal or neuropsychiatric diseases, first-degree relatives with dementia, past or current abuse of alcohol or other drugs, intake of psychoactive drugs or antiinflammatory medication (up to 6 weeks before inclusion) and structural abnormalities on MRI. AD patients were recruited through the Memory Clinics of the University Hospitals Leuven and the University Hospital Brussels. The main inclusion criteria were: diagnosis of probable AD according to the NINCDS-ADRDA criteria [17] , an MRI scan obtained within the last 12 months consistent with a diagnosis of AD, a positive [ 11 C]PIB scan (by visual assessment of a trained nuclear medicine physician), a modified Hachinski ischaemia scale score of ≤4 and a global clinical dementia rating (CDR) score [18] between 1 and 3 (or if the global CDR was 0.5, then the sum of boxes was at least 3.5). Recent or routine use of antiinflammatory medication (6 weeks) was also an exclusion criterion in AD patients.
On the day of the PET scan, all subjects underwent a full clinical examination, and blood and urine testing to exclude major disorders and drug abuse. Initially for each group ten subjects were recruited. However, due to high-performance liquid chromatography (HPLC) metabolite quantification problems in two HC and failure of full PET data acquisition in one anxious AD patient, full quantitative datasets were available in eight HC and nine AD patients. Four HC underwent retest scanning within a mean of 9 weeks. The main demographic and clinical/neuropsychological characteristics of the included subjects are presented in Table 1 .All participants underwent clinical neurological and neuropsychological evaluation within 2 weeks of the [ 11 C]NE40 PET scan (for details, see Supplementary Table 1 ). The study was approved by the local Ethics Committee and written informed consent was obtained from all participants.
Radioligand preparation
]NE40 was prepared as described previously [19] . Briefly, a helium stream containing [ C]NE40 was determined using reversed-phase HPLC. Injected radioactivity and specific activity for both subject groups can be found in Table 1 . [ 11 C]PIB was prepared as described previously [20] .
Imaging procedure
All subjects were scanned on a HiRez Biograph 16 PET/CT camera (Siemens, Knoxville, TN). All subjects fasted for 4 h before PET scanning. Prior to scanning, a radial artery cannula was inserted for blood sampling as well as a venous cannula on the contralateral side for injection. The subject's head was restrained by a vacuum cushion to reduce movement artefacts during the scan. Following the low-dose (11 mAs) CT transmission scan, a bolus of about 220 MBq (see Table 1 ) [ 11 C]NE40 was injected intravenously and a 90-min emission acquisition was started in list mode. All frames were Fourier rebinned into 26 frames: 4 frames of 15 s, 3 frames of 1 min, 3 frames of 2 min and 16 frames of 5 min. Images were reconstructed using an OSEM algorithm (five iterations, eight subsets).
Plasma input curves and metabolite analysis
In all subjects, 2-ml arterial blood samples were withdrawn manually at the following times: every 10 s for the first 100 s, at 120, 140 and 160 s, and at 3, 4, 5, 8, 10, 15, 20, 30, 40, 60, 74 and 90 min after injection. Additional 5-ml arterial samples were taken at 5, 10, 20, 40, 60 and 90 min to assess the fraction of unchanged [ 11 C]NE40 in plasma. All blood samples were centrifuged for 10 min at 3,000 rotations per minute (relative centrifuge force of 1,550 g). For metabolite analysis, 10 μg cold NE40 was added to 1 ml plasma and the mixture was injected onto the HPLC system as such. The HPLC eluent was collected in two fractions: 0 -15 min (metabolite fractions) and 15 -20 min (parent fraction). A Wallac 1480 gamma counter (PerkinElmer, Waltham, MA) was used to measure the amount of radioactivity in the plasma samples and each HPLC fraction for radiometabolite quantification. The parent fraction of the tracer as a function of time after tracer injection was fitted by a Hill function and then applied to the measured plasma activity resulting in a metabolite-corrected arterial input function.
Image analysis
Volume of interest segmentation
All data were segmented and modelled using PMOD version 3.4 (PMOD Technologies, Zurich, Switzerland). Interframe motion correction was applied. Individual T1-weighted MRI images were used for volume of interest (VOI) delineation (PNEURO tool). PET images were first rigidly coregistered to the corresponding individual volumetric T1-weighted MRI images. The individual T1-weighted MRI images were then nonlinearly coregistered to the standard Montreal Neurological Institute (MNI) space MRI template in PMOD. Subsequently the same was done for the PET images using the same spatial transformation as used for the registered MRI images. Initially, MRI images were segmented into fractions grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF). Next, the human brain probability maps with 83 VOIs (Hammers template [21] ) were applied. VOIs with expected homogeneous CB 2 R expression (cortex, subcortex, cerebellum) were united into bigger combination volumes to increase regional specificity. By this means the following 11 combined VOIs were defined: frontal, temporal, parietal and occipital lobes, striatum, thalamus, substantia nigra, cerebellum, insula, cingulate and total GM. GM, WM and CSF volumes were determined on all datasets by segmentation. The presence of brain atrophy was calculated by determining the GM volume relative to the sum of the GM, WM and CSF volumes. The dynamic [ 11 C]NE40 PET activity data (kilobecquerels per cubic centimetre) were spatially coregistered with the subject- The data presented are means ± standard deviation (except gender as number of subjects)
MMSE Mini-mental state examination, BDI Beck depression inventory, EOS end of synthesis *p < 0.05 vs. HC specific MRI, and the VOIs were projected onto the PET data to generate time-activity curves (TACs).
Kinetic modelling
A one-tissue (K 1 , k 2 ) kinetic model and two-tissue (2T) reversible (K 1 , k 2 , k 3 , k 4 ) and irreversible (K 1 , k 2 k 3 ) kinetic models with input functions corrected for blood volume and arterial metabolites were evaluated to calculate total distribution volume (V T ). Binding potential (BP ND ) was calculated as the ratio k 3 /k 4 from the 2T reversible kinetic model. Modelling was performed using weighting factors based on total activity per VOI per frame and frame durations. Various random starting parameter sets were used with each VOI to prevent the solution being stuck in a local minimum. The best kinetic model was selected based on the Akaike information criterion (AIC) [22] . Spectral analysis was applied to the data to confirm the optimal number of compartments that best fitted the experimental data [23, 24] . Data were calculated for both the global GM VOI, and, to assess regional variability, also for frontal, temporal, parietal, and cingulate cortex VOIs.
As AD patients may have substantial cortical atrophy which affects the rate of spill-out of the PET signal, partial volume correction was applied (Rousset method) within PMOD [25] . The comparison of V T and BP ND in the 11 combined VOIs as above calculated from partial volume-corrected data were compared using t tests.
Amyloid deposition was measured in AD patients on [ Images were reconstructed (into 6 × 5 min frames, checked for motion and added using rigid motion correction) and standardized uptake value ratios (SUVR) were calculated as described previously [26] . SUVR was defined by normalization of each VOI to the mean SUV in the cerebellar GM. Additionally, parametric SUVR amyloid images were coregistered to the subject's MRI scan that was spatially normalized to the MNI space as described above. A VOI analysis was performed using the same combined VOIs as for the [ 11 C]NE40 data. A VOI-based correlation analysis was performed between CB 2 R availability and amyloid deposition.
Statistical analysis
Differences in kinetic parameters between groups were evaluated using Student's t test. A p value of <0.05 was defined as statistically significant. Conventional statistics were performed using GraphPad Prism 6 and the p values of VOI comparisons were corrected for multiple comparisons using Bonferroni correction. Table 1 shows the basic demographic and scan data, as well as the results for the mini-mental state examination (MMSE) and Beck depression inventory. The HC were older than 40 years, as they also served as the control group in other studies, but were significantly younger than the AD patients. However, no correlation between age and CB 2 R availability in either subject groups was found for V T or BP ND values ( Supplementary  Fig. 1 ). The MMSE score was significantly lower in AD patients than in HC (p = 0.004). Two out of nine AD patients were using cholinesterase inhibitors during the study and one AD patient was using antidepressant medication. Details of the neuropsychological test results are presented in Supplementary Table 1 .
Results
Subject characteristics and neuropsychological evaluation
Blood input and PET imaging
The mean parent fraction of [ 
Kinetic modelling results
[
11 C]NE40 TAC were best fitted by a 2T reversible model (Fig. 2) , since the AIC indicated that a 2T reversible model was preferable in 12 subjects (71 %), and a 2T irreversible model was the best option in 4 patients (24 %). Only in one patient was a second compartment not necessary and an optimal fit was reached with a one-tissue model. Subjects with a better AIC score for an irreversible model could nevertheless The tracer demonstrated slow kinetics with a K 1 of 0.07 ml/ min/ml and k 4 of 0.027 1/min in HC ( Table 2 ). The test-retest variability, calculated as 1 − [parameter (day 1)/parameter (day 2)], was 28 % and 30 % for V T and BP ND , respectively, in a total GM VOI.
CB 2 R availability group comparison
The relative GM volume was significantly lower in the AD patients (0.50 ± 0.04) than in the HC (0.54 ± 0.02; p = 0.0078). Therefore, partial volume correction was applied in all PET datasets. Kinetic modelling showed that V T values for all regions were very low (about 1.3 for HC and 1.0 for AD patients), indicating low binding of the tracer throughout the brain in both groups. Furthermore, CB 2 R availability was significantly lower in AD patients than in HC for V T , and this applied to all grouped cortical regions (p < 0.001; Table 2 ). A trend towards lower BP ND was seen in the total GM in AD patients (p = 0.08), and for the temporal lobe VOI the difference was significant (p = 0.047). The regional variation in kinetic parameters and the variance of the k values are also shown in Table 2 . The regional variation was very low, while the variance of the k values was of the order 20 -30 %, and in some AD patients up to 50 %.
The average V T for all VOIs (Fig. 3 and Supplementary Table 2 ) was significantly lower in AD patients than in HC. Fig. 2 Time-activity curves in target regions of a representative AD patient (GM total grey matter, CB cerebellum, FL frontal lobe, TL temporal lobe, PL parietal lobe, Cing cingulate). Insert shows the total and metabolitecorrected plasma time-activity curve for the same AD patient The data presented are means ± standard deviation and are corrected for the partial volume effect by the Rousset method a Distribution volume obtained by Logan graphical analysis Figure 4 shows BP ND and V T values in individual regions in the two subject groups. Overall BP ND and V T values were low in all regions in both groups. There was no region with higher regional binding in AD patients than in HC. Figure 5 shows orthogonal images of mean CB 2 R parametric maps of V T .
Correlation of CB 2 R availability with amyloid deposition and MMSE score in AD patients
There was no regional correlation for homologous VOIs between amyloid deposition and CB 2 R availability, and there was no correlation between CB 2 R availability and neuropsychological test results.
Discussion
In this work we used [ 11 C]NE40, a novel radioligand for CB 2 R, as a tentative marker for activated microglia, and studied its kinetic modelling in the brain of HC and AD patients. AD patients did not show higher CB 2 R availability than HC as was hypothesized from preclinical and post-mortem literature. In contrast, AD patients showed overall significantly lower CB 2 R availability throughout the brain, both in cortical and subcortical regions. Moreover, no correlation was found between regional amyloid deposition and homologous CB 2 R availability in AD patients.
Regarding kinetic modelling of [ 11 C]NE40, a 2T reversible model provided the best results, and both BP ND and V T could be used to quantify CB 2 R availability. [ 11 C]NE40 showed relatively slow kinetics, and with a combination of the constants K 1 = 0.07 ml/min/ml and k 3 and k 4 close to 0.02 -0.03 1/min, the tracer accumulated and dissipated slowly in the bound compartment, enabling appropriate quantification over a 90-min period. Time stability of the kinetic parameters was not measured in this study. Test-retest variability for [ 11 C]NE40 was relatively poor for V T and BP ND (28 % and 30 %, respectively), but these values were based on low expression levels of activated microglia in the healthy brain and therefore low levels of CB 2 R can be assumed. Test-retest values in patients with markedly elevated levels of CB 2 R should therefore be considered to address test-retest in pathological circumstances, and the values obtained in HC should probably be considered the upper limits.
Previous studies on neuroinflammation in AD (for review, see Janssen et al. [27] ), mainly using TSPO markers, have in general shown a pattern of increased neuroinflammation, although some inconsistencies have been found. In AD, initial 11 C]PK11195 (a TSPO radioligand) in the frontal cortex [28] . In vivo, increased retention of [ 11 C]PK11195 in patients with mild to moderate AD was found in the entorhinal, temporoparietal and posterior cingulate cortex, corresponding to areas that also show glucose hypometabolism [5] . Kreisl et al. reported a greater TSPO signal using [ 11 C]PBR28 in AD patients than in MCI and control subjects, in whom TSPO binding was correlated with disease severity and GM loss [29] . However, a recent study by Golla et [31, 32] . The AD patients in the studies by Varrone et al. and those in the present study showed comparable MMSE scores (25 ± 3). However, as in all these studies rs6971 TSPO polymorphism genotyping was not performed [33] , the high variance from grouping patients as low, medium and high binders may explain the negative results obtained.
However, a number of explanations could account for the observed lack of upregulation of CB 2 R in AD patients. Although [ 11 C]NE40 is a high-affinity and selective PET radioligand for CB 2 R (Ki human CB 2 R = 9.6nM; Ki human CB 1 R = 1,000 nM) [19] , indicating a 100-fold selectivity over CB 1 R, it is known that the CB 1 R is one of the most abundantly expressed receptors in the human brain (B max > 1 pmol/mg protein) [34] . In contrast, the expression level of CB 2 R in brain is a matter of debate, and to the best of our knowledge, no values for B max of CB 2 R in brain tissue have yet been reported. Therefore, regarding sensitivity, the nanomolar affinity of [ 11 C]NE40 for CB 2 R may not be good enough for detecting neuroinflammation. Also, regarding selectivity, it is therefore conceivable that the measured signal is still influenced by off-target selectivity to CB 1 R. However, this cannot explain the observed lower CB 2 R availability in AD patients compared with that in HC, as we recently found that partial volume-corrected CB 1 R availability is not altered in AD patients compared with controls [26] . To address this issue in vivo, CB 1 R inverse agonist blockade studies could be performed, but these are difficult in view of the withdrawal of CB 1 R inverse agonists from the market [35] .
Moreover, several studies have shown that CB 2 R in the brain may be expressed not only on activated microglia but also on neuronal cells. Van Sickle et al. reported the presence of CB 2 R mRNA and protein in brainstem neurons [36] , while Gong et al. [37] and Onaivi et al. [38] studied the distribution of CB 2 R in healthy adult rat brain and found low levels of neuronal CB 2 R expression in the cerebellum, and cortical and subcortical regions. Fernandez-Ruiz et al. reported expression of CB 2 R in microglia, astrocytes and neuronal subpopulations, using a variety of neurodegenerative disease models [39] . A recent study by Savonenko et al. in an AD mouse model showed CB 2 R immunoreactivity in activated microglia, and also in neuronal cells [8] . The authors found an enhanced CB 2 R signal that was attributed to microglial activation instead of neuronal cell loss. It may therefore be possible that the CB 2 R PET signal in this study derives not only from microglial CB 2 R but also from neuronal CB 2 R expression, and the lower CB 2 R availability in AD patients could be explained by a loss of neuronal cells expressing CB 2 R that is incompletely compensated by atrophy correction.
A limitation of our study was that the HC who were also included in other pathological studies were significantly younger than the AD patients. However, no correlation was found between age and [ 11 C]NE40 uptake in either the HC or the AD patients ( Supplementary Fig. 1 ). Therefore it seems unlikely that our results were influenced by this confounder.
In conclusion, using appropriately quantifiable [ 11 C]NE40 PET, we found a lack of upregulation of CB 2 R in the brain of AD patients in vivo compared with HC without any correlation with regional amyloid deposition. In contrast, CB 2 R availability was significantly lower in AD patients, and this may indicate a relative loss of neuronal expression rather than absence of microglial expression, therefore making the CB 2 R target less promising as a biomarker for neuroinflammation in AD.
